Access to safe and effective pediatric medicines is crucial but remains challenging, especially in low- and middle-income countries (LMICs). Barriers such as inadequate regulatory frameworks, market disincentives, and limited investment hinder access to essential pediatric medications. Global pediatric legislation aims to address these challenges by promoting drug development tailored for children, enhancing regulatory oversight, and improving access to medicines. Key components of such legislation include incentives for pharmaceutical companies, such as market exclusivity extensions and priority review vouchers, to encourage pediatric formulations and clinical trials. Despite these efforts, LMICs face hurdles in implementation due to financial and infrastructural limitations. Strengthening regulatory capacity and ensuring ethical research practices are vital. Global initiatives, including those by the WHO and the Gates Foundation, play significant roles in supporting pediatric medicine development and addressing the health needs of children in LMICs. Collaboration among stakeholders is essential to overcome disparities and improve public health outcomes, ensuring better access to medicines for children worldwide.